Latest Erythropoiesis-stimulating agents Stories
RARITAN, N.J. and SAN ANTONIO, Dec.
Phosphate Binder Combination Use in Dialysis is Low, According to Findings from Decision Resources Group BURLINGTON, Mass., Sept.
AllMed webinar provides in-depth review of the latest standard of care for the use of ESAs in the treatment of Chronic Kidney Disease. Portland, OR (PRWEB) August
THOUSAND OAKS, Calif., Aug.
In patients with a traumatic brain injury (TBI), neither the administration of the hormone erythropoietin (EPO) or maintaining a higher hemoglobin concentration through blood transfusion resulted in improved neurological outcome at 6 months.
DUBLIN, March 28, 2014 /PRNewswire/ -- Dublin - Research and Markets ( http://www.researchandmarkets.com/research/8zbxmj/investigation) has announced the addition of the
ChinaMarketResearchReports.com adds Latest Report on “Investigation Report on China Epoetin Alfa Market, 2009-2018” to its store. Dallas, TX (PRWEB) March
The CKD Market Will Decline Through 2017, Due to Genericization of Expensive Agents and Reimbursement Constraints in the U.S., According to Findings from Decision Resources Group BURLINGTON,
- A trick or prank.